Covid 19 Research using Clinical Trials (Home Page)
Report for D008569: Memory Disorders NIH
(Synonyms: Memory Disorders)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2836 | Technology based social interactions Wiki | 1.00 |
| drug1895 | No research related technology based social interactions Wiki | 1.00 |
| drug376 | Baricitinib Wiki | 0.38 |
| drug2413 | Remdesivir Wiki | 0.23 |
| drug2122 | Placebo Wiki | 0.05 |
Correlated MeSH Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000544 | Alzheimer Disease NIH | 0.50 |
| D060825 | Cognitive Dysfunction NIH | 0.32 |
Correlated HPO Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002354 | Memory impairment HPO | 1.00 |
| HP:0002511 | Alzheimer disease HPO | 0.50 |
| HP:0001268 | Mental deterioration HPO | 0.32 |
There is one clinical trial.
Clinical Trials
1 Impact of Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults With and Without Cognitive Impairment
The current study will examine the impact of frequent social interaction through communication technologies during COVID-19 pandemic in the cognitive status of socially-isolated older adults with and without cognitive impairment. Patients will take place in an experimental crossover study, participants will complete one month of an intervention and one month of as passive control. The goal of this study is to determine: A.) if frequent social interaction through ICT during COVID-19 pandemic will have a significant positive impact in cognitive performance on testing, and B.) how social isolation and cognitive status influence misconceptions around the current pandemic.
NCT04480112 Memory Disorders Alzheimer Disease Mild Cognitive Impairment Behavioral: Technology based social interactions Other: No research related technology based social interactions MeSH:Alzheimer Disease Memory Disorders Cognitive Dysfunction
HPO:Alzheimer disease Cognitive impairment Memory impairment Mental deterioration
Primary Outcomes
Description: The Oral Trail Making Test B (TMT-B) will be used to assess memory performance. It is a neuropsychological measure that provides an assessment of sequential set-shifting. Participants are asked to count from 1 to 25 switching between number and letter, eg 1-A-2-B-3-C, until stopped.
Measure: Change in memory performance Time: Baseline,1 month
Description: Repeatable Battery for the Assessment of Neuropsychological Status (R-BANS) will be administered to assess cognitive decline or improvement. The 12 items on the RBANS assess five cognitive domains: immediate memory, visuospatial/constructional abilities, language, attention, and delayed memory. Scores can range from 0-160 and are interpreted as: 130 and above- very superior; 120-129 - superior; 110-119- high average; 90-109- average; 80-89- low average; 70-79- borderline; 60 and below extremely low.
Measure: Change in cognition Time: Baseline, 1 month
Description: Phonemic fluency will be assessed by asking participants to produce orally as many words as possible beginning with a specific letter or for a specific category (eg animals, fruits, etc). The test consists of three trials, of 1 min each. The higher the number of words provided, the greater the verbal fluency.
Measure: Change in phonemic fluency Time: Baseline, 1 month
Secondary Outcomes
Description: The 6-item version of the Lubben Social Network scale (LSNS-6) will be used to assess social isolation. For each of the 6 questions the participant rates from 0 to 5 their perceived social engagement where 0=less social engagement and 5= more social engagement. The summed total score ranges between 0 and 30. Lower total scores indicate more social isolation.
Measure: Social isolation Time: 1 month
Description: Loneliness will be assessed using the UCLA loneliness scale. Participants rate each item as either O ("I often feel this way"= 3),S ("I sometimes feel this way"=2), R ("I rarely feel this way"=1), N ("I never feel this way"=0). A total score is computed by adding up the response to each question and can range from 0 to 60. The average loneliness score on the measure is 20. A score of 25 or higher reflects a high level of loneliness. A score of 30 or higher reflects a very high level of loneliness.
Measure: Loneliness Time: 1 month
Description: The Geriatric Depression Scale (GDS) will be used to assess depression. It consists of 15 questions- 10 indicate the presence of depression when answered positively, while the rest (question numbers 1, 5, 7, 11, 13) indicate depression when answered negatively. Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.
Measure: Depressive symptoms Time: 1 month
Description: An investigator developed questionnaire based on survey results published by Geldsetzer P in Annals of Internal Medicine, 3-2020 will be used to assess Covid-19 misinformation.
Measure: Misinformation about Covid-19 Time: 1 month
HPO Nodes
HP:0002354: Memory impairment
Genes 169
TYROBP PDGFRB C9ORF72 TREM2 DNMT1 BAP1 IL12A CAMTA1 EIF2B3 GNE TERT TNFSF4 EIF2B4 FMR1 PSAP SMO CSF1R XPR1 TOMM40 SLC25A13 HLA-DRB1 MYORG REEP2 CHMP2B VCP PDGFB SORL1 PMS2 PRKCG SIM1 GRN TREM2 VAMP1 BMPR1A EPCAM NOTCH3 MEFV TRNF IL12A-AS1 BAP1 MEN1 SPG7 PSEN1 IL10 MAPT UGT1A1 PSEN1 APP PSEN1 PRKAR1B MAPT STAT4 DNMT1 IL23R MAPT ERAP1 CP PIK3CA CHMP2B CCR1 VPS13A SPG7 ND1 ND4 MLH3 MSH2 HLA-DQB1 KLRC4 ACSF3 KCNQ3 ATXN3 SMARCB1 COX1 SCN2A SQSTM1 MSH6 PMS1 TRNW VAMP1 PRNP TRNQ DNMT1 ND5 AKT1 SPAST JPH3 ATXN3 MOG PRNP MLH1 PSEN2 GSN ND6 RRM2B HLA-B KRAS MYD88 ABCA7 APP PRNP PRNP MAPT HLA-DQB1 SLC20A2 TGFBR2 RNASEH1 COX3 HCRT GRN C9ORF72 TREX1 FMR1 C4A EIF2B1 TMEM106B UBAC2 ALDH18A1 POLG ZNF365 SCN8A ABCA7 RPS20 PSEN1 AFG3L2 FGF14 ATN1 ATXN1 MAPT P2RY11 COX2 STUB1 C9ORF72 TREM2 SEMA4A PDGFB ARSA TRNS2 KCNQ2 EIF2B5 TREM2 PAH PRNP CHMP2B APOE SMARCE1 MAPT EIF2B2 ATXN3 PSEN2 TMEM106B TRAF7 PRRT2 SUFU ECM1 TRNS1 TLR4 ADA2 GRN TRNL1 PIK3CA TWNK TRNH VCP FGF14 FAN1 NF2 FAS TYROBP CTSH Protein Mutations 0
SNP 0
Primary Outcomes
Description: The Oral Trail Making Test B (TMT-B) will be used to assess memory performance. It is a neuropsychological measure that provides an assessment of sequential set-shifting. Participants are asked to count from 1 to 25 switching between number and letter, eg 1-A-2-B-3-C, until stopped.
Measure: Change in memory performance Time: Baseline,1 monthDescription: Repeatable Battery for the Assessment of Neuropsychological Status (R-BANS) will be administered to assess cognitive decline or improvement. The 12 items on the RBANS assess five cognitive domains: immediate memory, visuospatial/constructional abilities, language, attention, and delayed memory. Scores can range from 0-160 and are interpreted as: 130 and above- very superior; 120-129 - superior; 110-119- high average; 90-109- average; 80-89- low average; 70-79- borderline; 60 and below extremely low.
Measure: Change in cognition Time: Baseline, 1 monthDescription: Phonemic fluency will be assessed by asking participants to produce orally as many words as possible beginning with a specific letter or for a specific category (eg animals, fruits, etc). The test consists of three trials, of 1 min each. The higher the number of words provided, the greater the verbal fluency.
Measure: Change in phonemic fluency Time: Baseline, 1 monthSecondary Outcomes
Description: The 6-item version of the Lubben Social Network scale (LSNS-6) will be used to assess social isolation. For each of the 6 questions the participant rates from 0 to 5 their perceived social engagement where 0=less social engagement and 5= more social engagement. The summed total score ranges between 0 and 30. Lower total scores indicate more social isolation.
Measure: Social isolation Time: 1 monthDescription: Loneliness will be assessed using the UCLA loneliness scale. Participants rate each item as either O ("I often feel this way"= 3),S ("I sometimes feel this way"=2), R ("I rarely feel this way"=1), N ("I never feel this way"=0). A total score is computed by adding up the response to each question and can range from 0 to 60. The average loneliness score on the measure is 20. A score of 25 or higher reflects a high level of loneliness. A score of 30 or higher reflects a very high level of loneliness.
Measure: Loneliness Time: 1 monthDescription: The Geriatric Depression Scale (GDS) will be used to assess depression. It consists of 15 questions- 10 indicate the presence of depression when answered positively, while the rest (question numbers 1, 5, 7, 11, 13) indicate depression when answered negatively. Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.
Measure: Depressive symptoms Time: 1 monthDescription: An investigator developed questionnaire based on survey results published by Geldsetzer P in Annals of Internal Medicine, 3-2020 will be used to assess Covid-19 misinformation.
Measure: Misinformation about Covid-19 Time: 1 month